Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Vismodegib
Drug ID BADD_D02365
Description Vismodegib inhibits the hedgehog signalling pathway and is indicated for treatment of adult basal cell carcinoma. FDA approved on Jan 30, 2012.
Indications and Usage Vismodegib is used for treating locally advanced or metastatic basal cell carcinoma in patients whose carcinoma has recurred after surgery, and in patients who are not candidates for surgery or radiation.
Marketing Status Prescription
ATC Code L01XJ01
DrugBank ID DB08828
KEGG ID D09992
MeSH ID C538724
PubChem ID 24776445
TTD Drug ID D03EDQ
NDC Product Code 50242-140
Synonyms HhAntag691 | NSC 747691 | NSC747691 | NSC-747691 | R 3616 | R3616 cpd | R-3616 | vismodegib | erivedge | GDC 0449 | GDC0449 | GDC-0449 | RG 3616 | RG3616 | RG-3616
Chemical Information
Molecular Formula C19H14Cl2N2O3S
CAS Registry Number 879085-55-9
SMILES CS(=O)(=O)C1=CC(=C(C=C1)C(=O)NC2=CC(=C(C=C2)Cl)C3=CC=CC=N3)Cl
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Not AvailableNot AvailableNot AvailableNot AvailableNot Available
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Irritability08.01.03.011; 19.04.02.013--
Jaundice23.03.03.030; 09.01.01.004; 01.06.04.0040.002398%Not Available
Joint stiffness15.01.02.0030.000533%Not Available
Joint swelling15.01.02.004--Not Available
Keratoacanthoma23.08.02.007; 16.03.02.0070.000533%Not Available
Laceration23.03.11.004; 12.01.06.0060.000533%Not Available
Lethargy19.04.04.004; 17.02.04.003; 08.01.01.008--
Lipase increased13.05.01.0030.000799%
Liver disorder09.01.08.0010.001066%Not Available
Liver function test abnormal13.03.01.0130.002398%Not Available
Localised infection11.01.08.0060.000533%Not Available
Loss of consciousness17.02.04.004--Not Available
Lower respiratory tract infection22.07.01.002; 11.01.09.0020.000533%Not Available
Lung infiltration22.01.02.0040.000533%Not Available
Lymphocyte count decreased13.01.06.0060.005328%
Lymphoma16.20.01.001; 01.12.01.0010.000139%Not Available
Malaise08.01.01.003--
Malignant melanoma16.03.01.001; 23.08.01.0010.001598%Not Available
Mass08.03.05.0030.000533%Not Available
Melaena24.07.02.013; 07.12.02.004--Not Available
Memory impairment19.20.01.003; 17.03.02.003--
Menopause26.03.01.001--Not Available
Metastases to lung22.08.01.005; 16.22.02.0020.000208%Not Available
Metastatic malignant melanoma23.08.01.002; 16.03.01.0020.000139%Not Available
Mood altered19.04.02.007--Not Available
Mouth ulceration07.05.06.0040.000799%Not Available
Muscle spasms15.05.03.0040.093510%
Muscle twitching15.05.03.0050.001332%Not Available
Muscular weakness17.05.03.005; 15.05.06.001--
Musculoskeletal pain15.03.04.0070.001332%
The 6th Page    First    Pre   6 7 8 9 10    Next   Last    Total 12 Pages